A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Parabilis Medicines, Inc.
City of Hope Medical Center
NuCana plc
M.D. Anderson Cancer Center
AstraZeneca